Treatment Development & Evaluation Core

治疗开发

• 批准号: 10624448
• 负责人: Lisa A. Marsch
• 金额: $ 35.27万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10624448
• 关键词: AIDS prevention; Acceleration; Address; Adherence; Adolescent; Adult; Advanced Development; Agitation; Applications Grants; Area; Assessment tool; Behavior Therapy; Behavior monitoring; Cellular Phone; Clinical; Collection; Communities; Consultations; Data; Decision Making; Development; Diagnosis; Diagnostic; Digital biomarker; Doctor of Philosophy; Education; Educational Activities; Educational workshop; Effectiveness; Ethics; Etiology; Evaluation; Evidence based treatment; Exercise; Experimental Designs; Faculty; Fostering; Funding; Goals; Grant; Health; Heart Rate; Individual; Intervention; Location; Measurement; Mental Health; Mentors; Mentorship; Methods; Minority; Minority Groups; Minority Health Research; Outcome; Outcome Study; Paper; Participant; Persons; Pharmacotherapy; Phenotype; Physiologic Monitoring; Population; Population Heterogeneity; Postdoctoral Fellow; Privacy; Process; Process Assessment; Public Health; Publishing; Reduce health disparities; Relapse; Research; Research Personnel; Research Priority; Research Project Grants; Resource Sharing; Resources; Risk; Science; Services; Sleep disturbances; Specificity; Students; Substance Use Disorder; Targeted Research; Technology; Therapeutic; Therapeutic Research; Time; Training; Treatment Protocols; Underrepresented Minority; adaptive intervention; cost; digital; digital assessment; digital health; digital treatment; dual diagnosis; evidence base; health assessment; improved; innovation; intervention effect; novel; personalized therapeutic; phenotypic data; physical conditioning; recruit; social contact; substance use; substance use treatment; success; therapy design; therapy development; usability; wearable sensor technology; webinar

TREATMENT DEVELOPMENT AND EVALUATION CORE PROJECT SUMMARY Digital therapeutics hold great promise in overcoming the substantial challenges in accessing high quality, empirically supported treatments for substance use disorders (SUDs) and co-occurring mental or physical health conditions (CODs). Digital innovations can enhance the potency of existing interventions, extend their reach, and reduce costs. Digital biomarkers from behavioral and physiological monitoring using smartphones and wearable sensors (i.e., passive sensing) can improve specificity of assessment processes that in turn can provide personalized targets to optimize interventions. Supporting the development of digital therapeutics is vital, as most persons with SUDs do not receive SUD treatment, and of those who do receive treatment, only a minority of treatments are evidence-based. Over the past 9 years, the Treatment Development and Evaluation (TDE) Core has supported activities that enhance and expedite research on an array of technologies that can improve treatment delivery. Our Core affiliates’ research has advanced the feasibility, acceptability, usability, and efficacy of innovative digital health assessment tools and interventions for multiple types of SUDs among diverse populations. These projects have also improved our understanding of developmental, and maintaining factors, and mechanisms of change for SUDs. In the proposed renewal period, the TDE Core will continue to enhance the quality, efficiency, and impact of research projects among an interdisciplinary expert faculty. The Core will continue with, and expand activities for, sharing resources among CTBH affiliates and the greater scientific and clinical communities (Aim 1), and provide mechanisms to support the acceleration and accumulation of science that will enhance our understanding of factors that can optimize digital therapeutics for SUDs and CODs (Aim 2). These efforts will embrace the 5 new CTBH priorities (e.g., scaling of digital therapeutics, digital measurement to inform personalized just-in-time adaptive interventions (JITAIs), integration of CODs and transdiagnostic mechanisms and interventions, digital health ethics, and inclusion of underrepresented minority populations). For example, we will enhance our consultation services for preparing competitive grant applications by expanding the array of Advisors with expertise in the priority areas, and will refine the focus and enhance the intensity of our educational activities by developing and delivering webinars, tutorials, and cross-Core workshops that provide in-depth training on high priority research targets. The Core will also engage affiliates with active or pending digital health projects to include additional research aims that address our new priorities. e.g., add common metrics of outcomes related to scaling, mechanisms of change, or transdiagnostic processes; include passive sensing assessment to collect digital phenotyping data that may relate to substance use or relapse; and assess CODs in SUD projects to evaluate how they moderate intervention effects and how transdiagnostic interventions impact outcomes. These efforts will accelerate the state-of-the science of digital therapeutics for SUDs and related conditions across diverse populations.

治疗开发和评估核心项目摘要 数字疗法在克服获得高质量、 针对物质使用障碍 (SUD) 和同时发生的精神或身体障碍的经验支持治疗 健康状况 (COD)。数字创新可以增强现有干预措施的效力，扩大其影响 达到并降低成本。使用智能手机进行行为和生理监测的数字生物标记 可穿戴传感器（即被动传感）可以提高评估过程的特异性，从而可以 提供个性化目标以优化干预措施。支持数字疗法的发展是 至关重要，因为大多数患有 SUD 的人没有接受 SUD 治疗，而在接受治疗的人中，只有 少数治疗是基于证据的。过去9年来，治疗方法的开发和评估 (TDE) Core 支持加强和加快一系列技术研究的活动，这些技术可以 改善治疗实施。我们的核心附属机构的研究提高了可行性、可接受性、可用性、 创新数字健康评估工具和干预措施对多种类型 SUD 的有效性和有效性 不同的人群。这些项目还提高了我们对发展和维护的理解 SUD 变化的因素和机制。在拟议的续订期内，TDE Core 将继续 提高跨学科专家团队研究项目的质量、效率和影响力。这 Core 将继续并扩大 CTBH 附属机构和更大范围内的资源共享活动 科学和临床界（目标 1），并提供机制来支持加速和 科学的积累将增强我们对优化数字疗法的因素的理解 SUD 和 COD（目标 2）。这些努力将涵盖 5 个新的 CTBH 优先事项（例如，扩大数字化 治疗学、数字测量以告知个性化即时适应性干预措施 (JITAI)、 COD 与跨诊断机制和干预措施的整合、数字健康伦理以及纳入 少数族裔人口代表性不足）。例如，我们将加强为准备工作提供咨询服务。 通过扩大在优先领域具有专业知识的顾问阵容来竞争性资助申请，并将 通过开发和举办网络研讨会来细化重点并增强我们教育活动的强度， 教程和跨核心研讨会，提供有关高优先级研究目标的深入培训。核心 还将与正在进行或悬而未决的数字健康项目的附属机构合作，以纳入其他研究目标 解决我们新的优先事项。例如，添加与扩展、变革机制相关的结果的通用指标， 或跨诊断过程；包括被动传感评估，以收集可能的数字表型数据 与物质使用或复发有关；并评估 SUD 项目中的 COD，以评估它们如何调节 干预效果以及跨诊断干预如何影响结果。这些努力将加速 针对不同人群的 SUD 和相关病症的数字疗法的最新科学进展。